However, the clinical potential of MAO-B inhibitors to attenuate oxidative stress by inhibiting MAO-induced hydrogen peroxide production remains to be shown as clinical evidence of improved oxidant status in PD patients is lacking. The gene discussed is MAOB; the disease is Parkinson disease.